Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,583

Document Document Title
WO/2020/170840A1
The present invention addresses the problem of providing a novel crystal of 2-O-α-D-glucosyl-L-ascorbic acid and a method for producing the crystal. The problem is solved by providing a crystal of the potassium salt of 2-O-α-D-glucosyl...  
WO/2020/160443A1
Methods for preparing a polyene macrolide antifungal with improved aqueous solubility. The method involves providing a polyene macrolide antifungal having a carboxylic acid group; activating the carboxylic acid group; introducing a prima...  
WO/2020/132480A1
Compositions for treating an autoimmune, inflammatory, fibrotic, or proliferative disease or disorder comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, ...  
WO/2020/127843A1
The present disclosure relates to a compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each ...  
WO/2020/119773A1
The present disclosure relates to the field of medicine, and specifically relates to an amphotericin B peptide derivative and a preparation method therefor. The amphotericin B peptide derivative has a broad-spectrum and highly effective ...  
WO/2020/115661A1
A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a c...  
WO/2020/104697A1
The present invention relates to a synthetic saccharide of general formula (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical...  
WO/2020/106636A1
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13- membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions ...  
WO/2020/106780A1
Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene car...  
WO/2020/106627A1
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13- membered macrolides, pharmaceutical compositions ...  
WO/2020/079224A1
This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using ...  
WO/2019/075214A3
Disclosed are methods of treating cystic fibrosis using AmB and a sterol or compositions comprising AmB and a sterol. Also disclosed are methods of increasing the pH of airway surface liquid in a patient having cystic fibrosis using AmB ...  
WO/2020/057546A1
A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following...  
WO/2020/048049A1
Disclosed are a method for preparing a Luo Han Guo sweetner composition from Siraitia grosvenorii and a use thereof. The method for extracting the sweetener composition from Siraitia grosvenorii preferably comprises the following steps: ...  
WO/2020/050663A1
The present invention relates to a method for chemical production of 3,6-anhydro-L-galactitol (L-AHGol), which is a novel sugar alcohol, and agarobititol (ABol), which is a disaccharide having the same agarobititol as a reductant end the...  
WO/2020/051465A1
Disclosed are derivatives of amphotericin B (AmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the AmB derivatives, therapeutic methods of us...  
WO/2020/038279A1
A substituted pyrazole compound represented by formula I, and a preparation method, a pharmaceutical composition, and use thereof. The compound has good stability, excellent solubility, small cell toxicity, and a significant effect on ne...  
WO/2020/040233A1
The present invention provides a method for obtaining a specifically-shaped crystal (specifically, spherocrystal) of a compound with good reproducibility. This method for producing a specifically-shaped crystal (specifically spherocrysta...  
WO/2020/035553A1
The present invention is directed to a process for purifying natamycin, to an epoxide polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric macr...  
WO/2020/035552A1
The present invention is directed to a process for purifying natamycin, to an all-trans polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric ma...  
WO/2020/032752A1
The present invention relates to a catechin compound or a pharmaceutically acceptable salt thereof, and a use thereof, and a catechin compound or a pharmaceutically acceptable salt thereof of the present invention is very effective in th...  
WO/2020/032744A1
The present invention relates to a catechin compound or a pharmaceutically acceptable salt thereof, and a use thereof, and a catechin compound or a pharmaceutically acceptable salt thereof of the present invention is very effective in th...  
WO/2020/029168A1
A natamycin superfine powder, a preparation method therefor and the use thereof. The natamycin superfine powder is a solid powder, and has no fixed shape under a transmission electron microscope, and no less than 95% of the shape size is...  
WO/2020/021574A1
Pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I) for modulating one or more cytokines such as: Tumor necrosis factor-α (TNF-α), Interleukin-1 (IL-1), Interleuki...  
WO/2020/005111A1
The invention relates to chemistry and pharmacology, specifically to polymer complexes of a macrolide antibiotic. The claimed substance is a product of the interaction of a macrolide antibiotic with a copolymer of acrylamide and 2-acryla...  
WO/2019/241895A1
Provided are transgenic organisms, such as plants and plant parts, cells, and related compositions and methods for producing and monitoring the genotype for enhanced production of montbretin A and/or its precursors. For example, provided...  
WO/2019/241947A1
Disclosed is a method of separating and purifying icariin from Epimedium extract, relating to the technical field of separating and purifying a single component from a plant extract, and is intended to address the issues of complicated p...  
WO/2019/241461A1
The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.  
WO/2019/030367A8
The present invention relates to a method for the synthesis of compounds useful in the preparation of antibody drug conjugates (ADC), namely, monoprotected dimeric bifunctional prodrugs based on duocarmycin analogs. In a further aspect, ...  
WO/2019/228260A1
The present invention relates to a crystal form I of tenvermectin B. The crystal form I of tenvermectin B can be represented by means of an X-ray powder diffraction (XRPD) spectrum, an infrared (IR) absorption spectrum, a differential sc...  
WO/2019/191352A9
Disclosed herein are methods, sodium-dependent glucose transporter (SGLT)1 compounds and compositions for the treatment of postprandial hypoglycemia, postprandial hypoglycemia that occurs as a consequence of gastric surgery.  
WO/2019/201268A1
Disclosed are a drug used for preventing and/or treating pain and/or fever, a combination product, and a use thereof; the active ingredient of said drug comprises one of carrimycin, isovaleryl spiramycin III, isovaleryl spiramycin II, an...  
WO/2019/191830A1
The present application relates generally to the treatment of integumentary wounds (including chronic and acute wounds involving both cutaneous and mucous membranes), and in particular to topical formulations and instillates comprising o...  
WO/2019/191352A1
Disclosed herein are methods, sodium-dependent glucose transporter (SGLT)1 compounds and compositions for the treatment of postprandial hypoglycemia, postprandial hypoglycemia that occurs as a consequence of gastric surgery.  
WO/2019/182087A1
The present invention provides a novel process for preparing an oligosaccharide C-glycoside derivative of formula I, comprising reacting a compound of formula II with compound of formula III in the presence of at least one primary or sec...  
WO/2019/180265A1
The present invention provides a combination of immune stimulating macrolides with checkpoint inhibitors. The combinations have synergistic effects and can be used in treating viral diseases and cancer.  
WO/2019/180417A1
Amorphous ivermectinis provided, suitably in isolated solid form, and is suitably free of any additives or a support matrix, such as a solid dispersion. Also provided is a pharmaceutical formulation, for animal including human or veterin...  
WO/2019/178119A1
Disclosed are aminocoumarin compounds, pharmaceutical compositions containing aminocoumarin compounds, and methods of their use, e.g., in the treatment of a Gram- negative bacterial infection.  
WO/2019/141209A1
A pyranoglucose-substituted pyrazole compound, used as a pharmaceutical intermediate, having the structural formula represented by formula (9c). The present invention further relates to an intermediate compound represented by formula (10...  
WO/2019/135010A1
The invention relates to a compound according to formula (1), wherein R1 to R4 and X are independently from each other a small functional group and R5 is -OH, or a moiety consisting of specific combinations of -L-, -Ra-, -Rb-, -Rd- and R...  
WO/2019/119628A1
Disclosed in the present invention is a method for preparing tulathromycin.  
WO/2019/120830A1
The invention relates to ascorbic 3-xyloside derivative compounds of formula (I) and also the salts thereof, the solvates thereof and the optical isomers thereof, the geometric isomers thereof, the tautomers thereof, and/or the racemic m...  
WO/2019/069297A3
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...  
WO/2019/112567A1
This invention provides protease activity screening matrices that contain a solid support conjugated to a substrate moiety that can be specifically cleaved by a specific protease. The invention also provides methods for utilizing the pro...  
WO/2018/067663A3
The present invention relates to ketolide compounds of Formula I. The compounds have good anti-microbial activities, reduced inhibition of cytochrome P4503 A4 (CYP3 A4), and acceptable safety of co-administration of other drugs. The pres...  
WO/2019/091287A1
The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among c...  
WO/2019/069297A2
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...  
WO/2019/047848A1
The invention belongs to the field of quality analysis and control of traditional Chinese medicine, and provides a method for separating eighteen components in a traditional Chinese medicine composition, comprising: (1) preparing the tra...  
WO/2019/044941A1
The purpose of the present invention is to provide a novel compound that has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare, which are pathogens implicated in MAC infection, and has a backbone structu...  
WO/2019/036537A1
In one aspect, the present disclosure provides trioxacarcin analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein ...  

Matches 1 - 50 out of 6,583